BioAge Labs, Inc. (NASDAQ: BIOA)

This lawsuit is for anyone who acquired securities in BioAge Labs, Inc. (NASDAQ: BIOA) from September 26, 2024 through January 7, 2025.

The lawsuit alleges that the Company and certain of its executives violated federal law. Specifically, the lawsuit alleges that, in the Prospectus to the Company’s IPO, the Company misled investors regarding its financial condition. More specifically, the lawsuit alleges that the Company misled investors by failing to timely disclose to investors that its investigational drug candidate azelaprag was causing liver transaminitis in some subjects in clinical trials.

On December 6, 2024, BioAge announced that it would discontinue the ongoing STRIDES Phase 2 study of its investigational drug candidate azelaprag after liver transaminitis was observed in some subjects receiving azelapgrag. On this news, the price of the Company’s stock dropped precipitously on unusually heavy trading volume and continues to trade at less than its IPO price as of the date of the filing of this lawsuit.

The Law Offices of Howard G. Smith seeks to recover damages on behalf of class members. If you acquired securities in BioAge Labs, Inc. (NASDAQ: BIOA) from September 26, 2024 through January 7, 2025 you may join the lawsuit by submitting your information online, or you may call the Law Offices of Howard G. Smith and speak to Mr. Smith directly to learn how he can protect your rights.